LAPTM4A and central nervous system cancer: TCGA combined with GTEx data analysis revealed high LAPTM4A expression in gliomas, GBM, and LGG, and differences in LAPTM4A expression in different clinicopathological groups, including grade, histological type, age, 1p/19q codeletion, IDH status, response to main therapy, and OS events in glioma patients.